Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
J Med Virol. 2023 Sep;95(9):e29096. doi: 10.1002/jmv.29096.
This study was aimed at investigating the risk of cytomegalovirus (CMV) disease among coronavirus disease 2019 (COVID-19) survivors. In this retrospective cohort study, we used the TriNetX research network to identify adults with and without COVID-19 between January 1, 2022 and December 31, 2022. Propensity score matching was used to match the patients with and without COVID-19. The primary outcome was the risk of CMV disease during the 90-day follow-up period. Two matched cohorts comprising 2 501 634 patients with balanced baseline characteristics were created using propensity score matching. During the follow-up period, patients with COVID-19 had a higher risk of CMV disease than those without COVID-19 (hazard ratio [HR], 2.55; 95% confidence interval: 2.01-3.23). The higher risk of CMV disease in the COVID-19 cohort compared with that of the non-COVID-19 cohort remained unchanged in the subgroup analyses by sex (men: HR, 1.85 [1.38-2.47]; women: HR, 2.31 [1.63-3.27]), age (18-64 years: HR, 2.21 [1.71-2.85]; ≥65 years: HR, 1.97 [1.20-3.25]), obesity (HR, 1.54 [1.04-2.30]), diabetes mellitus (HR, 1.50 [1.08-2.08]), cancer (HR, 3.10 [1.95-4.92]), glucocorticoid use (HR, 3.14 [2.45-4.02]), transplantation (HR, 1.38 [1.08-1.77]), and unvaccinated status (HR, 2.37 [1.82-3.08]). In conclusion, COVID-19 can increase the risk of CMV disease. Clinicians should be aware of the risk of CMV disease in patients with COVID-19.
这项研究旨在调查 2019 冠状病毒病（COVID-19）幸存者中巨细胞病毒（CMV）疾病的风险。在这项回顾性队列研究中，我们使用 TriNetX 研究网络，于 2022 年 1 月 1 日至 2022 年 12 月 31 日期间，确定了患有 COVID-19 和未患有 COVID-19 的成年人。使用倾向评分匹配来匹配患有和未患有 COVID-19 的患者。主要结局是在 90 天随访期间 CMV 疾病的风险。使用倾向评分匹配创建了两个匹配队列，每个队列包含 2501634 名具有平衡基线特征的患者。在随访期间，患有 COVID-19 的患者发生 CMV 疾病的风险高于未患有 COVID-19 的患者（风险比 [HR]，2.55；95%置信区间：2.01-3.23）。在按性别（男性：HR，1.85 [1.38-2.47]；女性：HR，2.31 [1.63-3.27]）、年龄（18-64 岁：HR，2.21 [1.71-2.85]；≥65 岁：HR，1.97 [1.20-3.25]）、肥胖（HR，1.54 [1.04-2.30]）、糖尿病（HR，1.50 [1.08-2.08]）、癌症（HR，3.10 [1.95-4.92]）、糖皮质激素使用（HR，3.14 [2.45-4.02]）、移植（HR，1.38 [1.08-1.77]）和未接种疫苗（HR，2.37 [1.82-3.08]）的亚组分析中，COVID-19 队列发生 CMV 疾病的风险高于非 COVID-19 队列。总之，COVID-19 会增加 CMV 疾病的风险。临床医生应意识到 COVID-19 患者发生 CMV 疾病的风险。
